Servier is a global pharmaceutical group governed by a Foundation, with its headquarters in France. Relying on a solid geographical presence and revenue of €5.3 billion in 2023 achieved in 150 countries, Servier employs 21,900 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities, from research to support beyond the pill. A leader in cardiology, the ambition of the Servier Group is to become a focused and innovative player in oncology. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
--
To report a suspected adverse event with our drug, please visit servier.com